Sector: Professional, Scientific, and Technical Services Industry: Research and Development in Biotechnology (except Nanobiotechnology)
8.28
0.17
(2.096%)
Volume:
145,043
52 week range:
6.02 - 13.14
Market Cap:
584.305M
Company Description:
zymeworks is a privately held biotherapeutics company that is developing best-in-class azymetric™ bi specific antibodies and antibody drug conjugates for the treatment of oncology, autoimmunity and inflammatory diseases. the company’s novel azymetric™ and albucore™ platforms, and its proprietary zymecad™ structure-guided protein engineering technology, enable the development of highly potent bi-specific antibodies and multivalent protein therapeutics targeted across a range of indications. zymeworks is focused on accelerating its preclinical biotherapeutics pipeline through in-house research and development programs and strategic collaborations. more information on zymeworks can be found at www.zymeworks.com.